DE602006011574D1 - Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung - Google Patents

Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung

Info

Publication number
DE602006011574D1
DE602006011574D1 DE602006011574T DE602006011574T DE602006011574D1 DE 602006011574 D1 DE602006011574 D1 DE 602006011574D1 DE 602006011574 T DE602006011574 T DE 602006011574T DE 602006011574 T DE602006011574 T DE 602006011574T DE 602006011574 D1 DE602006011574 D1 DE 602006011574D1
Authority
DE
Germany
Prior art keywords
heterologous
management
manufacture
polypeptides
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006011574T
Other languages
German (de)
English (en)
Inventor
Robert Forgan Halenbeck
Elizabeth Bosch
Thomas Linnemann
Ernestine Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Five Prime Therapeutics Inc
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of DE602006011574D1 publication Critical patent/DE602006011574D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE602006011574T 2005-01-27 2006-01-27 Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung Active DE602006011574D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64701305P 2005-01-27 2005-01-27
PCT/US2006/002951 WO2006081430A2 (en) 2005-01-27 2006-01-27 Leader sequences for directing secretion of polypeptides and methods for production thereof

Publications (1)

Publication Number Publication Date
DE602006011574D1 true DE602006011574D1 (de) 2010-02-25

Family

ID=36741080

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006011574T Active DE602006011574D1 (de) 2005-01-27 2006-01-27 Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung

Country Status (9)

Country Link
US (1) US20080286834A1 (enExample)
EP (1) EP1841874B1 (enExample)
JP (2) JP2008528033A (enExample)
AT (1) ATE454455T1 (enExample)
AU (1) AU2006207999A1 (enExample)
CA (1) CA2589895A1 (enExample)
DE (1) DE602006011574D1 (enExample)
DK (1) DK1841874T3 (enExample)
WO (1) WO2006081430A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
US9060961B2 (en) * 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
WO2009056330A1 (en) * 2007-10-31 2009-05-07 Eth Zurich Soluble truncated apom proteins and medical uses thereof
EP2271358B1 (en) * 2008-03-25 2018-11-21 Amarantus Therapeutics, Inc. use of mesencephalic astrocyte-derived neurotrophic factor for treating Parkinson's disease
FR2933773B1 (fr) * 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
EP2318529B1 (en) 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
US8470554B2 (en) * 2008-12-22 2013-06-25 St. Jude Children's Research Hospital Prokaryotic expression of soluble, active Dkk
JP2010183885A (ja) * 2009-02-13 2010-08-26 Kobe Univ タンパク質の製造方法およびそれに用いる発現ベクター
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
EP2498799B1 (en) 2009-11-13 2016-08-17 Five Prime Therapeutics, Inc. Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2
HRP20191129T1 (hr) 2009-11-24 2019-09-20 Alethia Biotherapeutics Inc. Anti-klusterinska protutijela i ulomci koji vežu antigen i njihova uporaba za smanjivanje volumena tumora
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
ES2706412T3 (es) 2010-05-04 2019-03-28 Five Prime Therapeutics Inc Anticuerpos que se unen a CSF1R
WO2012006027A1 (en) 2010-06-28 2012-01-12 Five Prime Therapeutics, Inc. Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules and treatments using same
EP2444495A1 (en) * 2010-10-20 2012-04-25 Algenics Secretion of recombinant polypeptides in the extracellular medium of diatoms
CA2817583A1 (en) 2010-11-15 2012-05-24 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
CA2824805A1 (en) 2011-01-14 2012-07-19 Five Prime Therapeutics, Inc. Il-27 antagonists for treating inflammatory diseases
AU2012318247B2 (en) 2011-11-14 2015-12-17 Five Prime Therapeutics, Inc. Methods of treating cancer
EA201491568A1 (ru) 2012-02-22 2014-11-28 Алетиа Байотерапьютикс Инк. Совместное применение ингибитора кластерина и ингибитора egfr для лечения рака
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
JP6561378B2 (ja) 2012-06-08 2019-08-21 トランスレイト バイオ, インコーポレイテッド 非肺標的細胞へのmRNAの経肺送達
KR20150047593A (ko) 2012-08-31 2015-05-04 파이브 프라임 테라퓨틱스, 인크. 집락 자극 인자 1 수용체(csf1r)에 결합하는 항체로 질환을 치료하는 방법
ES2968649T3 (es) 2012-12-07 2024-05-13 Translate Bio Inc Nanopartículas lipídicas para la administración de ARNm en los pulmones
US20160184458A1 (en) 2013-03-14 2016-06-30 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
ME03476B (me) 2013-08-01 2020-01-20 Five Prime Therapeutics Inc Nefukozilisana anti-fgfr2iiib antitijela
SG11201610672YA (en) 2014-06-23 2017-01-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2016069727A1 (en) 2014-10-29 2016-05-06 Five Prime Therapeutics, Inc. Combination therapy for cancer
TW201630937A (zh) 2014-12-22 2016-09-01 戊瑞治療有限公司 用於治療pvns之抗-csf1r抗體
AU2016235362B2 (en) 2015-03-23 2021-12-16 Jounce Therapeutics, Inc. Antibodies to ICOS
CA2980460A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
KR20180066236A (ko) 2015-10-22 2018-06-18 조운스 테라퓨틱스, 인크. Icos 발현을 계측하기 위한 유전자 특질
CN109414481B (zh) 2016-04-25 2022-11-01 葛兰素史克知识产权开发有限公司 用于治疗病理性肌肉损失和虚弱的nope
CN110392694B (zh) 2016-11-02 2023-08-04 震动疗法股份有限公司 针对pd-1的抗体及其用途
WO2018144097A1 (en) 2016-11-04 2018-08-09 Akeagen Llc Genetically modified non-human animals and methods for producing heavy chain-only antibodies
JP2020504756A (ja) * 2016-12-29 2020-02-13 ディベロップメント センター フォー バイオテクノロジーDevelopment Center For Biotechnology タンパク質薬物のin vivo半減期延長のためのキニノーゲン−1由来ペプチド
CA3057687A1 (en) 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
EP3634988A4 (en) 2017-06-06 2021-02-24 Kindred Biosciences, Inc. ERYTHROPOIETIN AND SIMILAR COMPOUNDS FOR VETERINARY USE
CN111699196A (zh) 2017-12-22 2020-09-22 震动疗法公司 针对lilrb2的抗体
CN113056483B (zh) 2018-07-09 2025-08-01 戊瑞治疗有限公司 结合到ilt4的抗体
WO2020146857A1 (en) * 2019-01-11 2020-07-16 Arbele Limited Multispecific prochemokine therapeutic proteins (park) and method of making and using thereof
WO2021178001A1 (en) * 2020-03-05 2021-09-10 Curie Co. Inc. Methods for cell free protein expression of mature polypeptides derived from zymogens and proproteins
MX2022009947A (es) 2020-02-14 2022-11-07 Jounce Therapeutics Inc Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
MX2023001707A (es) 2020-08-10 2023-05-04 Shanghai Xunbaihui Biotechnology Co Ltd Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cánceres por direccionamiento al miembro 8 de la superfamilia de inmunoglobulinas.
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712114A (en) * 1995-06-06 1998-01-27 Basf Aktiengesellschaft Compositions for expression of proteins in host cells using a preprocollagen signal sequence
DE69902796T2 (de) * 1998-08-17 2003-08-07 Europaeisches Laboratorium Fuer Molekularbiologie (Embl) Verfahren zur reinigung von biomolekül- oder proteinkomplexen
US20080242603A1 (en) * 2004-02-20 2008-10-02 Yan Wang Novel Apo2L and IL-24 Polypeptides, Polynucleotides, and Methods of Their Use
JP5435865B2 (ja) * 2004-07-22 2014-03-05 ファイブ プライム セラピューティクス, インコーポレイテッド 疾患処置におけるmgd−csfのための組成物およびその使用方法

Also Published As

Publication number Publication date
DK1841874T3 (da) 2010-05-17
WO2006081430A2 (en) 2006-08-03
AU2006207999A1 (en) 2006-08-03
EP1841874A2 (en) 2007-10-10
JP2009131268A (ja) 2009-06-18
ATE454455T1 (de) 2010-01-15
WO2006081430A3 (en) 2007-04-05
EP1841874B1 (en) 2010-01-06
CA2589895A1 (en) 2006-08-03
JP2008528033A (ja) 2008-07-31
WO2006081430A9 (en) 2006-11-30
US20080286834A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
DE602006011574D1 (de) Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
PE20240728A1 (es) Sistemas de represores de casx disenados por ingenieria genetica
ATE478145T1 (de) Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
ATE521701T1 (de) Verbesserte konstrukte zur expression lysosomaler polypeptide
ATE449109T1 (de) Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
ATE541931T1 (de) Il-17-homologe polypeptide und ihre therapeutische verwendung
DK1294876T3 (da) EV-VEGF-nukleinsyrer og -polypeptider samt fremgangsmåder til deres benyttelse
KR100468977B1 (ko) 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
ATE406441T1 (de) Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
DK1616878T3 (da) Udskilte og membranspændende polypeptider samt nukleinsyrer kodende for disse
ATE448312T1 (de) Leitsequenzen zur verwendung bei der produktion von proteinen
EP4302824A3 (en) Compositions and methods for nucleic acid expression and protein secretion in bacteroides
ATE408016T1 (de) Verfahren zur herstellung und sekretion modifizierter peptide
EP3795586A3 (en) Production of proteins in labyrinthulomycetes
DK1756273T3 (da) Signalpeptid til frembringelse af et polypeptid
DE60130804D1 (de) Antagonistischer antikörper gegen pro842
ATE353969T1 (de) Expressionsvektoren, transformierte wirtszellen und fermentationsverfahren zur herstellung rekombinanter polypeptide
WO2003076569A3 (en) Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
ATE435914T1 (de) Induktion der blütenbildung
DE69926415D1 (de) Sekretiertes Polypeptide und dafür kodierende Nukleinsäuren
ATE429446T1 (de) Recombinante igf expressionssysteme
DK1621619T3 (da) Secernerede polypeptider og transmembran-polypeptider og nukleinsyrer, der koder for disse
ATE332308T1 (de) Sekretiertes und transmembranes polypeptid und dafür kodierende nukleinsäure
ATE396201T1 (de) Ausgeschiedene und transmembranpolypeptide und dafür kodierende nukleinsäure
DK1251173T3 (da) Secernerede og transmembrane polypeptider og nucleinsyrer kodende for disse

Legal Events

Date Code Title Description
8364 No opposition during term of opposition